GlassScriptPhysician profile
Edward K Myers
NPI 1568851020
$2,642.88
in general payments reported to CMS, 2019-2025
23 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $460 · 2023: $858 · 2024: $558 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,840.10 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,243.70 | 2021-2025 | |
| Gilead Sciences, INC. | $357.65 | 2022-2025 | Epclusa |
| Boston Scientific Corporation | $137.82 | 2025 | Intracept |
| Lilly USA, LLC | $117.54 | 2022-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $115.54 | 2023-2024 | |
| Astellas Pharma US INC | $104.01 | 2023-2024 | Veozah |
| Supernus Pharmaceuticals, INC. | $93.76 | 2023-2024 | Qelbree, Qelbree |
| Novo Nordisk INC | $71.74 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $49.45 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.39 | 2021-2025 | Jardiance |
| Abbott Laboratories | $39.87 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $30.63 | 2023-2024 | Farxiga, Airsupra |
| Melinta Therapeutics, LLC | $25.73 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.82 | 2025 | Caplyta |
| Genentech USA, INC. | $24.68 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.64 | 2025 | |
| Vanda Pharmaceuticals INC. | $21.65 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $21.49 | 2023 | Trintellix |
| Alexion Pharmaceuticals, INC. | $21.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.54 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $17.25 | 2021 | |
| Amgen INC. | $14.39 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.